Prosensa/GSK hopes for Phase III DMD recruitment boost from published data
This article was originally published in Scrip
Executive Summary
Netherlands-based biotech firm Prosensa is hoping that the publication of positive data from a Phase I/IIa trial and a 12-week extension study for its lead compound, PRO051 (GSK2402968), for the treatment of Duchenne Muscular Dystrophy (DMD), will help boost recruitment into a Phase III study it is conducting with GlaxoSmithKline for the product.